ReNAP

ReNAP is a Japanese biotechnology company specializing in the development of next-generation RNA therapeutics based on artificial circular RNA (circRNA) technology. Spun out from Kyoto University, the company utilizes the research of Professor Hirohide Saito to engineer RNA molecules with superior stability and translation efficiency compared to traditional linear mRNA. ReNAP's platform aims to address the limitations of current mRNA therapies, such as short half-life and high immunogenicity, by creating circularized structures that are resistant to exonuclease degradation. The company is currently advancing its pre-clinical pipeline focused on vaccines and protein replacement therapies for various medical needs. By leveraging its proprietary circularization and purification methods, ReNAP seeks to expand the therapeutic potential of RNA-based medicine.